ストックスクリーナーアプリを入手
1.13
10.32%
-0.13
前日終値:
$1.26
開ける：
$1.26
24時間の取引高:
87,463
Relative Volume:
0.20
時価総額：
$2.64M
収益：
$31,800
当期純損益:
$-37.83M
株価収益率:
-1.5915
EPS:
-0.71
ネットキャッシュフロー:
$-30.64M
1週間 パフォーマンス:
-18.12%
1か月 パフォーマンス:
-34.30%
6か月 パフォーマンス:
-97.15%
1年 パフォーマンス:
-98.57%
1日の値動き範囲:
$1.13
$1.26
1週間の範囲:
$1.13
$1.37
52週間の値動き範囲:
$1.13
$124.80
Eyenovia Inc Stock (EYEN) Company Profile
EYEN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EYEN
Eyenovia Inc
|
1.13 | 2.64M | 31,800 | -37.83M | -30.64M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-03-01 | 開始されました | Northland Capital | Outperform |
| 2020-02-03 | ダウングレード | Oppenheimer | Outperform → Perform |
Eyenovia Inc (EYEN) 最新ニュース
Deal Watch: Eyenovia Looks At New Direction In Proposed Merger With Betaliq - Citeline News & Insights
Eyenovia Inc expected to post a loss of $7.20 a shareEarnings Preview - TradingView
Eyenovia falls on plans to seek reverse merger - MSN
Eyenovia Enters Into Non-Binding Letter of Intent to Effect Reverse Merger With Betaliq - Vision Monday
Eyenovia And Betaliq Announce Potential Reverse Merger - Nasdaq
Eyenovia Shares Drop 14% Amid Betaliq Merger Talks - Yahoo Finance
Eyenovia stock falls on reverse merger plans (EYEN:NASDAQ) - Seeking Alpha
Eyenovia falls after plans to merge with private firm Betaliq - TradingView
Eyenovia Plans All-Stock Reverse Merger With Betaliq - MarketWatch
Eyenovia and Betaliq Explore Merger to Form New Ophthalmic Company Combining Innovative Drug Delivery Technologies for Glaucoma Treatment - Nasdaq
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq - GlobeNewswire
Strategic Merger Alert: Eyenovia and Betaliq Join Forces to Revolutionize Eye Care Delivery - StockTitan
EYENOVIA Earnings Preview: Recent $EYEN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Eyenovia, Inc. to Host Earnings Call - ACCESS Newswire
Eyenovia regains compliance with Nasdaq - MSN
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements - GlobeNewswire
Eyenovia Shares Surge After Regaining Nasdaq Compliance: What's Going On? - Benzinga
Eyenovia regains Nasdaq compliance, eyes strategic options By Investing.com - Investing.com Canada
Eyenovia regains Nasdaq compliance, eyes strategic options - Investing.com India
Eyenovia shareholders approve reverse stock split and additional stock reserve - MSN
Eyenovia Escapes Delisting Threat: What's Next for the Optejet Developer? - StockTitan
Eyenovia regains Nasdaq compliance with stock bid price By Investing.com - Investing.com Australia
Eyenovia regains Nasdaq compliance with stock bid price - Investing.com
Eyenovia, Inc. Announces Debt Restructuring, Including Amendment to Senior Secured Debt to Improve Liquidity - Vision Monday
Eyenovia defers debt payments to bolster liquidity By Investing.com - Investing.com Nigeria
Eyenovia announces debt restructuring, improving cash runway - MSN
Eyenovia, Inc. Announces Debt Restructuring Including - GlobeNewswire
Eyenovia defers loan payments, may convert debt to equity By Investing.com - Investing.com Canada
Eyenovia defers loan payments, may convert debt to equity - Investing.com India
Eyenovia defers debt payments to bolster liquidity - Investing.com India
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives - The Manila Times
Eyenovia, Inc. Announces Amendment to Senior Secured Convertible Debt to Enhance Liquidity and Support Optejet® Development - Nasdaq
Can This Biotech's Debt Restructuring Lead to a Strategic Sale? - StockTitan
FY2025 EPS Estimates for Eyenovia Boosted by HC Wainwright - Defense World
Eyenovia Inc’s (EYEN) Stock: A -58.29% Simple Moving Average for the Past 20 Days - The News Heater
Wainwright maintains neutral Eyenovia stock, $2 target - MSN
Wainwright maintains neutral Eyenovia stock, $2 target By Investing.com - Investing.com Canada
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device - GlobeNewswire
The Attractiveness of Investing In Eyenovia Inc (EYEN) is Growing - Knox Daily
Eyenovia, Inc. Announces Progress on Next-Generation User-Filled Optejet Dispensing Device - Marketscreener.com
Revolutionary Eye Drop Spray Shows Perfect Precision: Eyenovia's Game-Changing Solution for Millions - StockTitan
Eyenovia, Inc. Advances Development of User-Filled Optejet Device for Enhanced Ophthalmic Treatment - Nasdaq
Eyenovia enacts reverse stock split to meet Nasdaq requirements By Investing.com - Investing.com Australia
Eyenovia enacts reverse stock split to meet Nasdaq requirements - Investing.com
Eyenovia (NASDAQ:EYEN) Shares to Reverse Split on Monday, February 3rd - Defense World
Eyenovia Inc (EYEN) 財務データ
収益
当期純利益
現金流量
EPS
Eyenovia Inc (EYEN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rowe Michael M | Chief Executive Officer |
Aug 26 '24 |
Buy |
0.57 |
50,000 |
28,500 |
82,927 |
| Grant Stuart M. | 10% Owner |
Jul 02 '24 |
Buy |
0.66 |
1,515,151 |
1,000,000 |
10,914,153 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):